Slide 1: IMP761 webcast slides
For personal use only IMP761 webcast slides Date & Time: March 26, 2019, 7:45 am Australian Eastern Daylight Time March 25, 2019, 4:45 pm US Eastern Daylight Time Register: Interested parties can register via a link to the webcast on the Company’s website or via the following link: https://fnn.webex
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements For personal use only The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further
Slide 3: Targeting LAG-3/MHC II May Lead to Multiple Therapeutics in Numerous Indications
Targeting: LAG-3/MHC II May v Lead to Multiple Therapeutics in Numerous Indications For personal use only 3
Slide 4: The LAG-3 Agonist Concept
For personal use only The LAG-3 Agonist Concept 4
Slide 5: Targeting auto-reactive memory T cells in AID with IMP761
Targeting auto-reactive memory T cells in AID with IMP61 For personal use only AUTOIMMUNE DISEASES THE PRESENT: FIGHTING SYMPTOMS Treating general inflammation: corticoids, methotrexate, anti-TNF-α, -IL-6, -IL-17, -IL-23 mAbs THE FUTURE: FIGHTING THE CAUSE OF AID Treating the disease process: silenc
Slide 6: IMP761 works upstream from current therapeutic interventions
IMP761 works upstream from current therapeutic interventions For personal use only Auto-immune memory T cells are chronically stimulated by the same self-peptide, acquiring an ‘exhausted’ phenotype and expressing LAG-3 which down-modulates specifically TCR signaling. IMP761 increases this physiologi
Slide 7: IMP761: In Vitro Testing
For personal use only IMP761: In Vitro Testing 7
Slide 8: Inhibition of CD8 T cell proliferation
Inhibition of CD8 T cell proliferation For personal use only CFSE proliferation assay CFSElow % Divisons: Unstimulated 3 2 1 0 3.7% CEF 36.3% CEF peptide pool CEF + IMP761 CMV – EBV – Influenza 8.6% Stimulates CD8 T cells in hPBMCs 8
Slide 9: IMP761: In Vivo Testing
For personal use only IMP761: In Vivo Testing 9
Slide 10: Delayed-type hypersensitivity model in cynomolgus monkey
Delayed-type hypersensitivity model in cynomolgus monkey For personal use only Study design Immunofluorescence staining: IMP761/PBS inflammatory T cell infiltration at BCG1 BCG2 Tuberculin test 1 Tuberculin test 2 tuberculin test site before and after IMP761/PBS injection D-45 D-30 D-15/-13 D0 D1/3
Slide 11: IMP761 inhibits inflammatory T cell infiltration in vivo
IMP761 inhibits inflammatory T cell infiltration in vivo PBS / IMP761 For personal use only TB test 1 TB test 2 Inflammatory C D 3 in f ilt r aTt io celln infiltration testC1Dvs8 test 2 r a t io n in f ilt * ns % CD3+ cells * * infiltration 100 100 c e ll in filtr a tio n c e ll in filtr a tio n 50
Slide 12: Conclusion
Conclusion For personal use only • The Concept: treating the cause of autoimmune diseases, not just the symptoms • The Target: the self-peptide specific memory T cells harboring LAG-3 • The Tool: an agonistic LAG-3-specific mAb down-modulating self-peptide-induced TCR signaling • The Evidence (1): i
Slide 13: Thank you!
13 For personal use only Thank you!